{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-000209","form_type":"8-K","ticker":"EVFM","cik":"0001618835","company_name":"Evofem Biosciences, Inc.","filed_at":"2025-03-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.208948+00:00","generated_at":"2026-05-24T06:34:46.362869+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Evofem reports 2024 net sales up 6% to $19.4M; operating loss improved 57% YoY","bullets":["2024 net sales $19.4M (+6% YoY); operating loss $7.7M vs $17.8M in 2023, improvement of 57%.","Q4 2024 net sales $7.1M vs $4.8M Q4 2023; Q4 operating loss $1.0M vs $3.4M.","Sales & marketing expense fell to 47% of net sales for FY2024, down from 64% in 2023.","Merger with Aditxt: $1.5M funding due by Apr 7, 2025; stockholder meeting by Sep 26, 2025; close by Sep 30, 2025.","Raised $2.7M from Aditxt in Oct 2024; used to pay FDA obligations; year-end restricted cash $0.7M."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-000209","json":"https://secwatch.observer/filing/0001641172-25-000209.json","markdown":"https://secwatch.observer/filing/0001641172-25-000209.md","text":"https://secwatch.observer/filing/0001641172-25-000209.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1618835/000164117225000209/0001641172-25-000209-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1618835/000164117225000209/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T06:34:46.362869+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}